Re-engineered BCG overexpressing cyclic di-AMP augments trained immunity and exhibits improved efficacy against bladder cancer

Alok Kumar Singh; Monali Praharaj; Kara A. Lombardo; Takahiro Yoshida; Andres Matoso; Alex S. Baras; Liang Zhao; Geetha Srikrishna; Joy Huang; Pankaj Prasad; Jonathan D. Powell; Max Kates; David McConkey; Drew M. Pardoll; William R. Bishai; Trinity J. Bivalacqua

doi:10.1038/s41467-022-28509-z

Nature Communications (Feb 2022)

Re-engineered BCG overexpressing cyclic di-AMP augments trained immunity and exhibits improved efficacy against bladder cancer

Alok Kumar Singh,
Monali Praharaj,
Kara A. Lombardo,
Takahiro Yoshida,
Andres Matoso,
Alex S. Baras,
Liang Zhao,
Geetha Srikrishna,
Joy Huang,
Pankaj Prasad,
Jonathan D. Powell,
Max Kates,
David McConkey,
Drew M. Pardoll,
William R. Bishai,
Trinity J. Bivalacqua

Affiliations

Alok Kumar Singh: Johns Hopkins University, School of Medicine, Department of Medicine, Center for Tuberculosis Research
Monali Praharaj: Johns Hopkins University, School of Medicine, Department of Medicine, Center for Tuberculosis Research
Kara A. Lombardo: Johns Hopkins University, School of Medicine, Department of Urology
Takahiro Yoshida: Department of Urology, Hyogo Prefectural Nishinomiya Hospital
Andres Matoso: Department of Pathology, The Johns Hopkins University
Alex S. Baras: Department of Pathology, The Johns Hopkins University
Liang Zhao: The Bloomberg-Kimmel Institute for Cancer Immunotherapy at Johns Hopkins
Geetha Srikrishna: Johns Hopkins University, School of Medicine, Department of Medicine, Center for Tuberculosis Research
Joy Huang: Johns Hopkins University, School of Medicine, Department of Medicine, Center for Tuberculosis Research
Pankaj Prasad: Johns Hopkins University, School of Medicine, Department of Medicine, Center for Tuberculosis Research
Jonathan D. Powell: The Bloomberg-Kimmel Institute for Cancer Immunotherapy at Johns Hopkins
Max Kates: Johns Hopkins University, School of Medicine, Department of Urology
David McConkey: Johns Hopkins University, School of Medicine, Department of Urology
Drew M. Pardoll: The Bloomberg-Kimmel Institute for Cancer Immunotherapy at Johns Hopkins
William R. Bishai: Johns Hopkins University, School of Medicine, Department of Medicine, Center for Tuberculosis Research
Trinity J. Bivalacqua: Perelman School of Medicine at the University of Pennsylvania, Division of Urology, Department of Surgery

DOI: https://doi.org/10.1038/s41467-022-28509-z
Journal volume & issue: Vol. 13, no. 1
pp. 1 – 16

Abstract

Read online

Vaccination with BCG has been shown to induce a pre-priming effect in innate immune cells termed trained immunity. Here the authors re-engineer the BCG vaccine and show augmented immune responses, enhanced induction of trained immunity and improved antitumor efficacy in pre-clinical models of bladder cancer.

Published in Nature Communications

ISSN: 2041-1723 (Online)
Publisher: Nature Portfolio
Country of publisher: United Kingdom
LCC subjects: Science
Website: https://www.nature.com/ncomms/

About the journal